Nuclear Medicine Market Is Projected To Witness Growth Based On Increasing Number Of New Cancer & Cardiovascular Cases Till 2024:Grand View Research,inc.
The nuclear medicine market is expected to reach USD
13.8 billion by 2024, according to a new report by Grand View Research, Inc.
The burden of chronic diseases such as cancer and cardiac disorders is on rise.
Nuclear medicine products are widely used for diagnosis as well as treatment of
cancerous and cardiovascular disease.
The increasing prevalence of
these disorders poses direct impact on usage of radiopharmaceutical market. For
instance, as per the data published by the World Health Organization (WHO), the
incidences of cancer are anticipated to increase by 70.0% which is further
anticipated to drive the demand for radiopharmaceuticals.
The diagnostics when combined
with nuclear medicine improve on accuracy. The accuracy in the diagnosis has a
direct impact on the decision-making and treatment monitoring process. Adoption
of PET as a diagnostic tool is rapidly increasing since it has high accuracy
over other diagnostic techniques.
Browse full research report on Nuclear Medicine Market: http://www.grandviewresearch.com/industry-analysis/nuclear-medicines-market
Further key findings from
the study suggest:
- The product segments of nuclear medicine are divided
into diagnostic and therapeutic. Diagnostic products held commanding share
in 2015, this can be attributed to the advancements in scanning
technologies.
- Therapeutic products such as Alpha Emitters, Beta
Emitters and Brachytherapy are anticipated to exhibit lucrative growth.
- The key diagnostic application areas of nuclear
medicine formed the largest market in 2015. These applications are in
cardiology, neurology, oncology, and thyroid.
- North America owing to well-planned policies,
reimbursement structure, high healthcare spending and increasing awareness
dominated global nuclear medicine market in 2015.
- Asia Pacific is expected to witness lucrative growth
in coming eight years. Increasing per capita income and reform in policies
is favoring market players in terms of ease of doing business.
- The players in the nuclear medicine industry include
Eckert & Ziegler Group, Mallinckrodt Pharmaceuticals, GE Healthcare,
Jubilant Life Sciences, Bracco Imaging S.p.A, Nordion, Inc.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global nuclear
medicine market on the basis of product and region:
- Global
Product Outlook (Revenue, USD Million, 2013 - 2024)
- Diagnostics
- SPECT
- TC-99m
- TL-201
- GA-67
- I-123
- Others
- PET
- F-18
- RB-82
- Others
- Therapeutics
- Alpha
Emitters
- RA-223
- Beta
Emitters
- I-131
- Y-90
- SM-153
- Re-186
- Lu-117
- Others
- Brachytherapy
- Cesium-131
- Iodine-125
- Palladium-103
- Iridium-192
- Others
Regional Outlook (Revenue, USD Million, 2013 - 2024)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Mexico
- MEA
- South
Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment